ZengKui Guo1, Bhavani S Sahu2, Rongjun He3, Brian Finan3, Cheryl Cero2, Raffaello Verardi4, Maria Razzoli2, Gianluigi Veglia4, Richard D Di Marchi3, John M Miles1, Alessandro Bartolomucci5. 1. Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA. 2. Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN 55455, USA. 3. Novo Nordisk Research Center Indianapolis, Indianapolis, IN 46241, USA. 4. Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA. 5. Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: abartolo@umn.edu.
Abstract
TLQP-21 is a multifunctional neuropeptide and a promising new medicinal target for cardiometabolic and neurological diseases. However, to date its clearance kinetics and plasma stability have not been studied. The presence of four arginine residues led us to hypothesize that its half-life is relatively short. Conversely, its biological activities led us to hypothesize that the peptide is still taken up by adipose tissues effectively. [125I]TLQP-21 was i.v. administered in rats followed by chasing the plasma radioactivity and assessing tissue uptake. Plasma stability was measured using LC-MS. In vivo lipolysis was assessed by the palmitate rate of appearance. RESULTS: A small single i.v. dose of [125I]TLQP-21 had a terminal half-life of 110 min with a terminal clearance rate constant, kt, of 0.0063/min, and an initial half-life of 0.97 min with an initial clearance rate constant, ki, of 0.71/min. The total net uptake by adipose tissue accounts for 4.4% of the entire dose equivalent while the liver, pancreas and adrenal gland showed higher uptake. Uptake by the brain was negligible, suggesting that i.v.-injected peptide does not cross the blood-brain-barrier. TLQP-21 sustained isoproterenol-stimulated lipolysis in vivo. Finally, TLQP-21 was rapidly degraded producing several N-terminal and central sequence fragments after 10 and 60 min in plasma in vitro. This study investigated the clearance and stability of TLQP-21 peptide for the first time. While its pro-lipolytic effect supports and extends previous findings, its short half-life and sequential cleavage in the plasma suggest strategies for chemical modifications in order to enhance its stability and therapeutic efficacy.
TLQP-21 is a multifunctional neuropeptide and a promising new medicinal target for cardiometabolic and neurological diseases. However, to date its clearance kinetics and plasma stability have not been studied. The presence of four arginine residues led us to hypothesize that its half-life is relatively short. Conversely, its biological activities led us to hypothesize that the peptide is still taken up by adipose tissues effectively. [125I]TLQP-21 was i.v. administered in rats followed by chasing the plasma radioactivity and assessing tissue uptake. Plasma stability was measured using LC-MS. In vivo lipolysis was assessed by the palmitate rate of appearance. RESULTS: A small single i.v. dose of [125I]TLQP-21 had a terminal half-life of 110 min with a terminal clearance rate constant, kt, of 0.0063/min, and an initial half-life of 0.97 min with an initial clearance rate constant, ki, of 0.71/min. The total net uptake by adipose tissue accounts for 4.4% of the entire dose equivalent while the liver, pancreas and adrenal gland showed higher uptake. Uptake by the brain was negligible, suggesting that i.v.-injected peptide does not cross the blood-brain-barrier. TLQP-21 sustained isoproterenol-stimulated lipolysis in vivo. Finally, TLQP-21 was rapidly degraded producing several N-terminal and central sequence fragments after 10 and 60 min in plasma in vitro. This study investigated the clearance and stability of TLQP-21 peptide for the first time. While its pro-lipolytic effect supports and extends previous findings, its short half-life and sequential cleavage in the plasma suggest strategies for chemical modifications in order to enhance its stability and therapeutic efficacy.
Authors: Laura Molteni; Laura Rizzi; Elena Bresciani; Roberta Possenti; Pamela Petrocchi Passeri; Corrado Ghè; Giampiero Muccioli; Jean-Alain Fehrentz; Pascal Verdié; Jean Martinez; Robert J Omeljaniuk; Giuseppe Biagini; Anna Binda; Ilaria Rivolta; Vittorio Locatelli; Antonio Torsello Journal: Front Pharmacol Date: 2017-03-30 Impact factor: 5.810
Authors: Preeti H Jethwa; Amy Warner; Kanishka N Nilaweera; John M Brameld; John W Keyte; Wayne G Carter; Neil Bolton; Michael Bruggraber; Peter J Morgan; Perry Barrett; Francis J P Ebling Journal: Endocrinology Date: 2007-04-26 Impact factor: 4.736
Authors: Elia A Turolla; Silvia Valtorta; Elena Bresciani; Jean-Alain Fehrentz; Liliana Giuliano; Stefano Stucchi; Sara Belloli; Paolo Rainone; Francesco Sudati; Laura Rizzi; Laura Molteni; Pascal Verdiè; Jean Martinez; Antonio Torsello; Rosa Maria Moresco; Sergio Todde Journal: Front Pharmacol Date: 2018-11-13 Impact factor: 5.810
Authors: Carlo Lisci; Jo E Lewis; Zoe C T R Daniel; Tyler J Stevenson; Chloe Monnier; Hayley J Marshall; Maxine Fowler; Francis J P Ebling; Gian-Luca Ferri; Cristina Cocco; Preeti H Jethwa Journal: PLoS One Date: 2019-08-29 Impact factor: 3.240
Authors: Bhavani S Sahu; Pedro Rodriguez; Megin E Nguyen; Ruijun Han; Cheryl Cero; Maria Razzoli; Paolo Piaggi; Lauren J Laskowski; Mihaela Pavlicev; Louis Muglia; Sushil K Mahata; Scott O'Grady; John D McCorvy; Leslie J Baier; Yuk Y Sham; Alessandro Bartolomucci Journal: Cell Rep Date: 2019-09-03 Impact factor: 9.423
Authors: Elena Bresciani; Roberta Possenti; Silvia Coco; Laura Rizzi; Ramona Meanti; Laura Molteni; Vittorio Locatelli; Antonio Torsello Journal: Int J Mol Sci Date: 2019-12-24 Impact factor: 5.923
Authors: Bhavani S Sahu; Megin E Nguyen; Pedro Rodriguez; Jean Pierre Pallais; Vinayak Ghosh; Maria Razzoli; Yuk Y Sham; Stephen R Salton; Alessandro Bartolomucci Journal: Cell Mol Life Sci Date: 2021-10-09 Impact factor: 9.261